loading...| Preferred Name |
bacitracin |
|
| Synonyms |
BAC |
|
| Definitions |
A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C295" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C295" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000042858 |
|
| altLabel |
BAC |
|
| Component of | ||
| cui |
C0004599 |
|
| Date last modified |
2011-04-28 |
|
| definition |
A complex of cyclic polypeptide antibiotics, mainly bacitracin A, produced by spore-forming organisms belonging to the licheniformin group of the Bacillus subtilis with antibacterial activity. Bacitracin binds to C55-isoprenyl pyrophosphate, a biphosphate lipid transport molecule that carries the building blocks of the peptidoglycan bacterial cell wall. The binding interferes with the enzymatic dephosphorylation of the C55-isoprenyl pyrophosphate and prevents peptidoglycan synthesis, thereby inhibiting bacterial cell growth. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C295" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C295" NCI Thesaurus) |
|
| Legacy PDQ ID |
6668 |
|
| NCI ID |
C295 |
|
| notation |
CDR0000042858 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
bacitracin |
|
| tui |
T195 T116 |